Amer Zeidan, MD

February 07, 2022

Panelists look toward the future management of myelodysplastic syndromes with respect to novel agents and treatment pathways.

February 07, 2022

Experts reflect on interchangeability between oral and intravenous therapy in patients with higher-risk myelodysplastic syndromes.

January 31, 2022

Shared insight on the historical and current use of hypomethylating agents in patients with myelodysplastic syndromes.

January 31, 2022

Perspectives on the use of oral HMA therapy in higher-risk myelodysplastic syndromes, and how this has improved patient care.

January 24, 2022

Expert panelists discuss when it’s appropriate to consider or continue ESA therapy or blood transfusions in patients with MDS.

January 24, 2022

Panelists share insight on therapeutic goals when treating patients with myelodysplastic syndromes.

January 17, 2022

A brief review of disease and patient factors that influence the selection of therapy for myelodysplastic syndromes.

January 17, 2022

Reflections on the historical use of ESAs and blood transfusions to treat patients with myelodysplastic syndromes.

January 10, 2022

Experts consider shortcomings in the identification and management of myelodysplastic syndromes.

January 10, 2022

Practical perspectives on how to communicate MDS subclassifications with affected patients and caregivers.